Breaking News From ADA 2019

This page was last updated at 11:15am PT June 10, 2019.

Editor’s Note: this article will be updated regularly with breaking news and announcements during the course of the ADA Scientific Sessions Conference. Check back often! Follow along on twitter at #ADA2019

Monday, June 10 2019

• Two studies presented jointly by ADA + JDRF found that access to continuous glucose monitoring in children with diabetes improves glycemic control, reduces hypoglycemia and improves overall satisfaction with diabetes care and ease of technology use.

Sunday, June 9 2019

• Insulet announced positive trial results regarding the Omnipod® Horizon™ Hybrid Closed-Loop System. The study demonstrated that the system improved glycemic control and was safe for up to four days of use in children as young as two with type 1 diabetes (T1D).

• Study results were presented from Tandem’s Control-IQ hybrid closed loop using the t:slim X2 insulin pump with the Dexcom G6 continuous glucose monitor. Across 26 weeks, the group using Control-IQ performed better in every measurable outcome in the study. Participants using Control-IQ saw an increased time in range, lowered HbA1c and less time in hyperglycemia and hypoglycemia.

• According to two pivotal phase 3 studies, Eli Lilly and Company’s ultra rapid lispro (URLi) provided non-inferior A1C reductions compared to Humalog^® (insulin lispro) at 26 weeks in people with type 1 and type 2 diabetes. The data from these  studies also showed significant post-meal blood glucose (BG) reductions, one hour and two hours after a test meal compared to Humalog.

• TrialNet announced a breakthrough in type 1 diabetes prevention: the TrialNet Teplizumab Prevention Study focused on relatives of people with type 1 diabetes whose lifetime risk of developing T1D was thought to be 100 percent. During the trial, 72 percent of people in the control group receiving placebos developed type 1 diabetes, compared to only 43 percent of those receiving teplizumab.

Saturday, June 8 2019

• Study results showed that the iLet Bionic Pancreas increased time in range for adults with type 1 diabetes. BP significantly increased the percentage of time adults with T1D had blood glucose levels between 3.9-10.0 mmol/L70–180 mg/dL when compared to multiple daily injection (MDI) or pump usage.
• Medtronic announced the enrollment of study participants for the crucial Bluetooth Enabled MiniMed™ 780G advanced hybrid closed-loop system. This new technology features the delivery of automated correction boluses when users experience or are predicted to experience prolonged high BGs. Medtronic also announced that it initiated the pivotal trial for its next-generation Guardian™ Continuous Glucose Monitor (CGM) sensor, created to improve accuracy, reduce sensor calibrations and enhance overall user experience.
• New, evidence-based recommendations for time-in-range targets have been determined by an international panel of diabetes experts striving for accurate parameters for CGM blood glucose level goals in both research and clinical settings. While the panel explains that CGM-based targets must be personalized to meet the needs of each individual, there is a general consensus on recommendations based on data from large pre-CGM clinical trials, CGM randomized controlled trials and expert opinion.
• Abbott announced new data showing use of its FreeStyle Libre system significantly reduced hemoglobin A1c (HbA1c) levels for people living with type 2 diabetes on intensive insulin therapy. The results were analyzed from retrospective, real-world data in three countries across Europe and showed a nearly 1% drop in A1c from 8.9% to 8.0%.

Friday, June 7 2019

• Tidepool announced that they have partnered with Dexcom as first iCGM partner for the Tidepool Loop project, as well as Medtronic, which joins Insulet as a pump partner. Tidepool is working to build and support an FDA-regulated version of Loop that will work with commercially available insulin pumps and CGMs. Both announcements were made at #DData19. Further coverage coming soon!
• JDRF launched Impact Grants to fund projects and ideas that support people living with type 1 diabetes. The grants will fund up to $5,000 and individuals and nonprofit organizations  can apply.

Thursday, June 6 2019

• Abbott announced that the FreeStyle LibreLink app for Android users is now available in the U.S. The app was previously only available on iOS.
• Xeris Pharmaceuticals announced a PDUFA date extension for the Gvoke™ HypoPen. Instead of June 10, the Gvoke™ will receive an FDA decision by September 10, 2019.
• Senseonics announced that the Eversense CGM system received FDA approval for a non-adjunctive indication. Patients may have already been relying on Eversense for dosing, but this FDA approval marks a step towards one day using Eversense in a closed-loop system.
• Beta Bionics, Inc. and Zealand Pharma announced that a home-use study of dasiglucagon in the iLet™ Bionic Pancreas System has been successfully completed. The dual-hormone medical device autonomously controls blood-sugar levels in people with diabetes using insulin and dasiglucagon. The Phase 2 clinical trial demonstrated that the dual-hormone system provided superior glycemic control over the insulin-only version.

Wednesday, June 5 2019

• T1D Exchange and DreaMed Diabetes announced a partnership to optimize insulin treatment plans in clinics. Dream Advisor Pro, an AI-based support technology will be put to use in six clinics to best determine insulin delivery recommendations for particularly high-risk patients.

Tuesday, June 4 2019

• Ahead of the official start of ADA 2019, T1D Exchange announced Glooko as a partner in the ongoing Quality Improvement Collaboration. The effort will see one of the largest patient data sets ever to study type 1 diabetes.

Click here for complete coverage of ADA 2019 from Beyond Type 1.